Literature DB >> 10984120

Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers.

C Ghosh1, P L Iversen.   

Abstract

Antisense oligonucleotides inhibit gene expression by interfering with transcription, translation, or splicing. They show great potential as gene-specific, nontoxic therapy for a wide variety of diseases. They are also powerful tools to study gene function as well as for validation of therapeutic targets. Even with compelling evidence of activity in vivo, the majority of cell types in culture require technologies capable of efficiently delivering antisense oligonucleotides into the cytosolic/nuclear compartment of the cells in culture. Phosphorodiamidate morpholino oligomers (PMO) are a new generation of antisense oligomers with high specificity and efficacy. They inhibit translation of targeted mRNA by steric blockade. Different methods were evaluated for efficient delivery of PMO into the cells in culture. Efficacy was compared using the PMO targeted to the 5'-untranslated region (5'-UTR) of alpha-globin-luciferase reporter fusion gene mRNA. A functional assay based on the lunciferase reporter system was used to measure efficacy. The fluorescence-activated cell sorting (FACS) method was used for quantitative determination of PMO uptake into the cells. Physical methods, such as scrape-loading, syringe-loading, and osmotic-loading, provided efficient transfer of PMO into the cells, which resulted in higher efficacy. These procedures caused minimal damage to the cells. Cell permeabilization with streptolysin O did not improve the cell uptake of PMO. Complexation with cationic lipids, Lipofectin and Lipofectamine (GIBCO-BRL, Gaithersburg, MD) also failed to enhance the uptake of PMO. We conclude that physical methods are optimal for the delivery of neutrally charged PMO into cells in culture. Further, these methods do not leave residual material that may interfere with the interpretation of targeted gene function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984120     DOI: 10.1089/108729000421448

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  7 in total

1.  Triplex formation by morpholino oligodeoxyribonucleotides in the HER-2/neu promoter requires the pyrimidine motif.

Authors:  J Basye; J O Trent; D Gao; S W Ebbinghaus
Journal:  Nucleic Acids Res       Date:  2001-12-01       Impact factor: 16.971

2.  Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth.

Authors:  Benjamin W Neuman; David A Stein; Andrew D Kroeker; Amy D Paulino; Hong M Moulton; Patrick L Iversen; Michael J Buchmeier
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

3.  Peptide nucleic acid (PNA) cell penetrating peptide (CPP) conjugates as carriers for cellular delivery of antisense oligomers.

Authors:  Takehiko Shiraishi; Peter E Nielsen
Journal:  Artif DNA PNA XNA       Date:  2011 Jul-Dec

4.  Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers.

Authors:  Yan-Jin Zhang; Kai-Yu Wang; David A Stein; Deendayal Patel; Rheba Watkins; Hong M Moulton; Patrick L Iversen; David O Matson
Journal:  Antiviral Res       Date:  2006-06-14       Impact factor: 5.970

5.  Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.

Authors:  Yoshitsugu Aoki; Tetsuya Nagata; Toshifumi Yokota; Akinori Nakamura; Matthew J A Wood; Terence Partridge; Shin'ichi Takeda
Journal:  Hum Mol Genet       Date:  2013-07-23       Impact factor: 6.150

Review 6.  Microfluidic and Nanofluidic Intracellular Delivery.

Authors:  Jeongsoo Hur; Aram J Chung
Journal:  Adv Sci (Weinh)       Date:  2021-06-06       Impact factor: 16.806

7.  Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries.

Authors:  Abbie M Adams; Penny L Harding; Patrick L Iversen; Catherine Coleman; Sue Fletcher; Steve D Wilton
Journal:  BMC Mol Biol       Date:  2007-07-02       Impact factor: 2.946

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.